SUBSCRIBE
SUBSCRIBE

Kaleo Pharma

NEWS
Pictured: Doorway at the FTC building in Washingto
Policy
Three Companies Relent to FTC Demands, Delist Patents from FDA’s Orange Book
GSK withdrew three patents related to its asthma inhalers while Impax delisted both of its patents for Adrenaclick and Kaléo delisted eight patents covering Auvi-Q—the companies’ respective epinephrine auto-injectors.
December 22, 2023
 · 
2 min read
 · 
Kate Goodwin
BioCapital
Senators Question Kaleo Over 680% Price Hike of Naloxone Injector Evzio
February 10, 2017
 · 
1 min read
IN THE PRESS
Biotech Bay
U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure
July 18, 2023
 · 
3 min read
Business
Kaléo Expands Executive Team to Support Growth
June 27, 2023
 · 
1 min read
Business
Kaléo Adds Chief Business Officer to Executive Team
September 27, 2022
 · 
1 min read
Business
Kaléo Announces Executive Appointments and New Government Business Unit
August 11, 2022
 · 
6 min read
FDA
FDA Approves Kaléo’s 10 mg Naloxone Auto-Injector for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids
March 2, 2022
 · 
5 min read
Deals
Tredegar Completes the Sale of Ownership Interest in kaléo
December 28, 2021
 · 
3 min read
Deals
Marathon Asset Management Announces Acquisition of Kaléo
November 29, 2021
 · 
4 min read
Pharm Country
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
July 8, 2020
 · 
4 min read
Business
Walgreens and Kaléo Expand Retail Pharmacy Collaboration to Include AUVI-q® (epinephrine injection, USP) 0.1 mg, the Only FDA-Approved Epinephrine Auto-Injector for Infants and Toddlers, 16.5 – 33 lbs
July 11, 2019
 · 
10 min read
Business
Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide
September 6, 2018
 · 
8 min read
Load More
JOBS